Research programme: inborn metabolic disorder therapeutics - Agios Pharmaceuticals

Drug Profile

Research programme: inborn metabolic disorder therapeutics - Agios Pharmaceuticals

Alternative Names: IEM therapeutics - Agios Pharmaceuticals

Latest Information Update: 15 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glycolysis modulators; Pyruvate kinase stimulants; Thyroid hormone binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn genetic disorders
  • Research Beta-thalassaemia

Most Recent Events

  • 14 Nov 2016 Early research in Beta-thalassaemia in USA
  • 26 Nov 2013 Preclinical trials in Inborn genetic disorders in USA (unspecified route)
  • 20 Sep 2012 Early research in Inborn genetic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top